|1.||Abraham, William T: 5 articles (12/2012 - 04/2006)|
|2.||Ghali, Jalal K: 4 articles (05/2013 - 11/2010)|
|3.||Orlandi, Cesare: 4 articles (12/2012 - 10/2010)|
|4.||Decaux, Guy: 3 articles (02/2015 - 04/2003)|
|5.||Zmily, Hammam D: 3 articles (05/2013 - 11/2010)|
|6.||Rosner, Mitchell H: 2 articles (01/2013 - 12/2012)|
|7.||Josiassen, Richard C: 2 articles (12/2012 - 12/2012)|
|8.||Bichet, Daniel G: 2 articles (12/2012 - 12/2012)|
|9.||Daifallah, Suleiman: 2 articles (06/2011 - 11/2010)|
|10.||Soupart, Alain: 1 article (02/2015)|
01/01/2003 - "In conclusion, VPA-985 appears effective and safe in appropriate doses in correcting abnormal renal water handling and hyponatremia in conditions associated with water retention. "
10/01/2010 - "Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study."
01/01/2003 - "This study investigates the efficacy and safety of 3 different doses of the V(2) receptor antagonist, VPA-985, in correcting hyponatremia over a 7-day inpatient study period. "
07/01/2014 - "Treatment of hyponatremia: the role of lixivaptan."
06/01/2013 - "Lixivaptan and hyponatremia."
|2.||Body Weight (Weight, Body)
04/01/2003 - "Treatment with VPA-985 was associated with a significant reduction in urine osmolality and body weight. "
06/01/2012 - "In outpatients with HF and volume overload, lixivaptan 100 mg once daily, when added to standard therapy, reduced body weight, improved dyspnoea and orthopnoea, and was well tolerated. "
06/01/2012 - "Body weight decreased significantly from baseline to Day 1 with lixivaptan vs. placebo (least-square mean change ± standard error: - 0.38 ± 0.08 kg vs. +0.13 ± 0.11 kg; P < 0.001) and at Weeks 1, 2, and 4 (P < 0.01). "
10/01/2010 - "Lixivaptan was shown to increase serum sodium and reduce body weight, without renal dysfunction or hypokalemia. "
06/01/2012 - "The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study."
06/01/2008 - "Early data on lixivaptan in heart failure suggest a dose-dependent aquaresis effect, and larger studies are under way."
07/01/2012 - "Heart failure: Lixivaptan reduces volume overload in patients with heart failure."
06/01/2011 - "The available experience of lixivaptan in heart failure, although limited, is encouraging. "
11/01/2010 - "Ongoing phase III trials will determine the role of lixivaptan in the management of hyponatremia, especially when associated with heart failure."
05/01/2009 - "Studies so far have demonstrated that lixivaptan is efficacious in the correction of hyponatremia in SIADH, heart failure and liver cirrhosis with ascites, and few adverse effects have been noted. "
10/01/2012 - "Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia."
10/01/2012 - "To determine the effects of vaptans (tolvaptan, satavaptan and lixivaptan) on patients with cirrhosis and hyponatraemia or ascites. "
11/01/2010 - "Phase II clinical trials in patients with congestive heart failure, liver cirrhosis with ascites or syndrome of inappropriate antidiuretic hormone have demonstrated that, unlike traditional diuretics, lixivaptan increases water clearance without affecting renal sodium excretion or activating the neurohormonal system. "
04/01/2003 - "Sixty patients with cirrhosis and dilutional hyponatremia were randomly assigned to 100 or 200 mg/day of VPA-985 or placebo in a double-blind study. "
07/01/2001 - "Six hyponatremic patients with SIADH and 5 hyponatremic patients with cirrhosis with ascitis (CWAs) were treated with 50 or 100 mg VPA-985 twice daily. "
04/01/2003 - "Therefore, we investigated the effects of VPA-985, an orally active vasopressin V2 receptor antagonist, in patients with cirrhosis and dilutional hyponatremia. "
07/01/2001 - "Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985."
07/01/2001 - "Whether solute excretion is affected in patients with hyponatremia resulting from inappropriate secretion of antidiuretic hormone (SIADH) or from cirrhosis treated with VPA-985 is unknown. "
|6.||Vasopressin Receptors (Arginine Vasopressin Receptor)